Alcon shares jump 5.43% intraday after strong Q3 results with accelerated equipment growth and reaffirmed full-year guidance.

Alcon surged 5.43% intraday following the release of robust third-quarter 2025 results, driven by accelerated sales growth in equipment and ocular health segments. The company reported $2.6 billion in net sales, up 6% year-over-year, with equipment/other sales rising 13% due to strong demand for Unity VCS and PanOptix Pro. Vision Care sales grew 7%, supported by contact lenses and dry eye/glaucoma products. Alcon reaffirmed its full-year guidance despite prior downward revisions, easing investor concerns. CEO David Endicott highlighted "encouraging topline growth" and momentum in key markets, bolstering confidence in 2026 prospects. The stock’s rise aligned with positive analyst sentiment, as confirmed guidance and product traction offset higher tax expenses and tariff pressures.